Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Other Non Operating Income (2021 - 2025)

Historic Other Non Operating Income for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to -$56994.0.

  • InMed Pharmaceuticals' Other Non Operating Income fell 39515.28% to -$56994.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$104775.0, marking a year-over-year decrease of 189225.11%. This contributed to the annual value of -$28471.0 for FY2025, which is 5402.04% up from last year.
  • As of Q3 2025, InMed Pharmaceuticals' Other Non Operating Income stood at -$56994.0, which was down 39515.28% from $22137.0 recorded in Q2 2025.
  • InMed Pharmaceuticals' Other Non Operating Income's 5-year high stood at $59896.0 during Q4 2023, with a 5-year trough of -$96791.0 in Q3 2022.
  • Over the past 5 years, InMed Pharmaceuticals' median Other Non Operating Income value was -$22165.0 (recorded in 2025), while the average stood at -$18418.4.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first skyrocketed by 57299.63% in 2022, then plummeted by 166201.98% in 2024.
  • Over the past 5 years, InMed Pharmaceuticals' Other Non Operating Income (Quarter) stood at $3007.0 in 2021, then surged by 573.0% to $20237.0 in 2022, then soared by 195.97% to $59896.0 in 2023, then crashed by 179.73% to -$47753.0 in 2024, then dropped by 19.35% to -$56994.0 in 2025.
  • Its Other Non Operating Income was -$56994.0 in Q3 2025, compared to $22137.0 in Q2 2025 and -$22165.0 in Q1 2025.